Literature DB >> 21461184

Understanding the Role of the Death Receptor 5/FADD/caspase-8 Death Signaling in Cancer Metastasis.

Shi-Yong Sun1.   

Abstract

The normal function of the extrinsic apoptotic pathway is to mediate apoptosis. Thus, this pathway is generally recognized to be critical in host immune surveillance against cancer. However, many studies have suggested that some key components in this pathway including Fas, death receptor 5 (DR5), Fas-associated death domain (FADD) and caspase-8 may contribute to cancer growth or metastasis. Our recent study on DR5 and caspase-8 expression in human head and neck cancer tissues indicate that high caspase-8 either alone or along with high DR5 in tumor tissue from patients with lymph node metastasis is significantly associated with poor disease-free survival and overall survival, suggesting that these proteins may be involved in positive regulation of cancer metastasis. Thus, efforts should be made to better understand the role of the death receptor 5/FADD/caspase-8 death signaling in regulation of cancer metastasis.

Entities:  

Year:  2011        PMID: 21461184      PMCID: PMC3066014     

Source DB:  PubMed          Journal:  Mol Cell Pharmacol        ISSN: 1938-1247


  36 in total

1.  Potentiation of neuroblastoma metastasis by loss of caspase-8.

Authors:  Dwayne G Stupack; Tal Teitz; Matthew D Potter; David Mikolon; Peter J Houghton; Vincent J Kidd; Jill M Lahti; David A Cheresh
Journal:  Nature       Date:  2006-01-05       Impact factor: 49.962

2.  Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas.

Authors:  Guoan Chen; Mahaveer S Bhojani; Andrew C Heaford; Daniel C Chang; Bharathi Laxman; Dafydd G Thomas; Laura B Griffin; James Yu; Julia M Coppola; Thomas J Giordano; Lin Lin; David Adams; Mark B Orringer; Brian D Ross; David G Beer; Alnawaz Rehemtulla
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-18       Impact factor: 11.205

3.  Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.

Authors:  Heath A Elrod; Songqing Fan; Susan Muller; Georgia Z Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

4.  TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.

Authors:  Anne Grosse-Wilde; Oksana Voloshanenko; S Lawrence Bailey; Gary M Longton; Uta Schaefer; Andreea I Csernok; Günther Schütz; Erich F Greiner; Christopher J Kemp; Henning Walczak
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 5.  Targeting the extrinsic apoptosis pathway in cancer.

Authors:  Avi Ashkenazi
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-20       Impact factor: 7.638

6.  Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients.

Authors:  Gustave J Ullenhag; Abhik Mukherjee; Nicholas F S Watson; Ahmad H Al-Attar; John H Scholefield; Lindy G Durrant
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

7.  Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.

Authors:  Tom M Ganten; Jaromir Sykora; Ronald Koschny; Emanuela Batke; Sebastian Aulmann; Ulrich Mansmann; Wolfgang Stremmel; Hans-Peter Sinn; Henning Walczak
Journal:  J Mol Med (Berl)       Date:  2009-08-13       Impact factor: 4.599

8.  Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation.

Authors:  Imtiaz A Mawji; Craig D Simpson; Rose Hurren; Marcela Gronda; Moyo A Williams; Jorge Filmus; James Jonkman; Ralph S Da Costa; Brian C Wilson; Michael P Thomas; John C Reed; Gennadi V Glinsky; Aaron D Schimmer
Journal:  J Natl Cancer Inst       Date:  2007-05-16       Impact factor: 13.506

9.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.

Authors:  M J Smyth; E Cretney; K Takeda; R H Wiltrout; L M Sedger; N Kayagaki; H Yagita; K Okumura
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

10.  Rab5 mediates caspase-8-promoted cell motility and metastasis.

Authors:  Vicente A Torres; Ainhoa Mielgo; Simone Barbero; Ruth Hsiao; John A Wilkins; Dwayne G Stupack
Journal:  Mol Biol Cell       Date:  2009-11-18       Impact factor: 4.138

View more
  15 in total

1.  Sodium fluoride induces apoptosis and autophagy via the endoplasmic reticulum stress pathway in MC3T3-E1 osteoblastic cells.

Authors:  Xueyan Li; Li Meng; Feng Wang; Xiaojie Hu; Youcheng Yu
Journal:  Mol Cell Biochem       Date:  2018-12-05       Impact factor: 3.396

2.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

3.  Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer.

Authors:  X Wen; Z-Q Lin; B Liu; Y-Q Wei
Journal:  Cell Prolif       Date:  2012-03-20       Impact factor: 6.831

4.  Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.

Authors:  Getinet M Adinew; Samia S Messeha; Equar Taka; Ramesh B Badisa; Lovely M Antonie; Karam F A Soliman
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

Review 5.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Authors:  L Ouyang; Z Shi; S Zhao; F-T Wang; T-T Zhou; B Liu; J-K Bao
Journal:  Cell Prolif       Date:  2012-10-03       Impact factor: 6.831

6.  Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma.

Authors:  Songqing Fan; Susan Müller; Zhuo Georgia Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

7.  Structural Insight for Roles of DR5 Death Domain Mutations on Oligomerization of DR5 Death Domain-FADD Complex in the Death-Inducing Signaling Complex Formation: A Computational Study.

Authors:  Hongyi Yang; Yuhua Song
Journal:  J Mol Model       Date:  2016-03-19       Impact factor: 1.810

8.  MicroRNA expression signature in human abdominal aortic aneurysms.

Authors:  Matthew C Pahl; Kimberly Derr; Gabor Gäbel; Irene Hinterseher; James R Elmore; Charles M Schworer; Thomas C Peeler; David P Franklin; John L Gray; David J Carey; Gerard Tromp; Helena Kuivaniemi
Journal:  BMC Med Genomics       Date:  2012-06-15       Impact factor: 3.063

9.  Anticancer effect of tectochrysin in colon cancer cell via suppression of NF-kappaB activity and enhancement of death receptor expression.

Authors:  Mi Hee Park; Ji Eun Hong; Eun Sook Park; Hee Sung Yoon; Doo Won Seo; Byung Kook Hyun; Sang-Bae Han; Young Won Ham; Bang Yeon Hwang; Jin Tae Hong
Journal:  Mol Cancer       Date:  2015-06-30       Impact factor: 27.401

10.  Overexpression of angiopoietin-1 reduces doxorubicin-induced apoptosis in cardiomyocytes.

Authors:  Danyang Ren; Quan Zhu; Jiantao Li; Tuanzhu Ha; Xiaohui Wang; Yuehua Li
Journal:  J Biomed Res       Date:  2012-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.